Pharming Technologies

Pharming is a global biopharmaceutical company dedicated to developing innovative protein replacement therapies and precision medicines for the treatment of rare diseases and unmet medical needs. The company's flagship product, Ruconest, is a recombinant human C1 esterase inhibitor produced through its proprietary transgenic technology platform for the treatment of acute hereditary angioedema. Pharming recently expanded its portfolio with the commercial launch of Joenja (leniolisib), the first approved treatment for activated PI3K delta syndrome (APDS). The company maintains a robust pipeline focused on expanding the indications for its existing products and developing new therapies for rare immunologic and hematologic disorders. Pharming operates with a fully integrated business model, encompassing research, development, and internal manufacturing capabilities.